Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) announced a quarterly cash dividend of $1.30 per share for Q1 2026. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.
Johnson & Johnson (NYSE: JNJ) completed the acquisition of Halda Therapeutics OpCo for $3.05 billion in cash on December 29, 2025. The deal brings a clinical-stage oral prostate cancer therapy, HLD-0915, plus earlier RIPTAC™ platform candidates for breast, lung and other solid tumors.
J&J said the acquisition will be treated as a business combination and expects a total Adjusted EPS dilution of ~$0.20, split equally between Q4 2025 and 2026 due to non-recurring equity, financing and integration charges. Full-year 2026 guidance commentary is scheduled for the January 21, 2026 earnings call.
Johnson & Johnson (NYSE: JNJ) announced on December 18, 2025 that the U.S. Food and Drug Administration approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) to treat symptomatic subacute and chronic subdural hematoma (cSDH) as an adjunct to surgery.
The approval is supported by the randomized MEMBRANE trial, which showed TRUFILL n‑BCA was superior in effectiveness to standard of care and was demonstrated to be safe for cSDH. TRUFILL n‑BCA has been used in neurovascular embolization for over 25 years, with original FDA approval in 2000.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous formulation for EGFR-mutated NSCLC.
Key clinical highlights: SC administration reduces infusion time to ~5 minutes, showed an ARR rate of 13% vs 66% for IV, lower VTE incidence (11% vs 18%), and PK comparability per Phase 3 PALOMA-3. Combined with LAZCLUZE, prior MARIPOSA data showed a statistically significant OS benefit (HR 0.75; 95% CI 0.61–0.92; P=0.0048) at 37.8-month median follow-up; median OS was not reached and is projected to exceed four years.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Wednesday, January 21 to review fourth-quarter results. The call will be led by Joaquin Duato, CEO; Joseph J. Wolk, CFO; and Darren Snellgrove, VP Investor Relations, with additional executives joining the Q&A.
Investors can access the live webcast and presentation at www.investor.jnj.com. A webcast replay will be available about three hours after the call and by telephone until ~12:00 a.m. on February 4. The press release will be posted at ~6:45 a.m. ET the morning of the call. The company also notes the first-quarter 2026 date of Tuesday, April 14, 2026.
Johnson & Johnson (NYSE:JNJ) announced U.S. FDA approval on Dec 13, 2025 for AKEEGA® (niraparib + abiraterone acetate) plus prednisone for BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC).
Approval was based on Phase 3 AMPLITUDE results showing AKEEGA plus ADT reduced risk of radiographic progression or death by 54% (HR 0.46; 95% CI 0.32–0.66) and delayed symptomatic progression by 59% (HR 0.41; 95% CI 0.29–0.65).
The safety profile matched known monotherapy risks; common adverse reactions (≥20%) included hematologic abnormalities, fatigue, musculoskeletal pain, and hypertension.
Johnson & Johnson (NYSE:JNJ) reported Phase 3 MajesTEC-3 results showing TECVAYLI plus DARZALEX FASPRO significantly improved survival and response versus standard RRMM regimens at nearly three years follow-up.
Key outcomes: PFS HR 0.17 (83% risk reduction; P<0.0001), OS HR 0.46 (3-year OS 83.3% vs 65.0%), higher complete response (81.8% vs 32.1%), and higher MRD-negativity (58.4% vs 17.1%).
Safety: similar Grade 3/4 TEAE rates; higher infection rates but reduced after six months with prophylaxis.
Regulatory: sBLA submitted; U.S. FDA granted Breakthrough Therapy Designation and review via RTOR.
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast will be available on Johnson & Johnson’s Investor Relations website at www.investor.jnj.com, with an archived edition published later the same day. The audio webcast replay will be available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) reported updated CARTITUDE-4 Phase 3 results showing durable, treatment-free remissions with CARVYKTI as early as second line for relapsed or refractory multiple myeloma. In the as-treated standard-risk subgroup, the 30-month progression-free survival (PFS) rate plateaued at 80.5% (95% CI, 67.2–88.8) after a single infusion (median follow-up 33.6 months).
Of 176 patients treated in second line, 59 had standard-risk cytogenetics; all 26 patients who were MRD-negative CR at 12 months remained progression-free at 30 months. Translational analyses linked earlier-line use to stronger immune fitness (increased baseline CD4+ naïve T cells), which correlated with longer PFS.
Johnson & Johnson (NYSE:JNJ) reported Cohort 4 results from the Phase 2b SunRISe-1 study showing the gemcitabine intravesical system produced a one-year disease-free survival (DFS) of 74.3% (95% CI, 59.2-84.6) in BCG-unresponsive, high-risk, papillary-only NMIBC patients.
At median follow-up of 15.9 months, one-year progression-free survival was 95.6% and overall survival was 98%. 92.3% of patients did not undergo radical cystectomy. Treatment was generally well tolerated, with mostly low-grade urinary side effects and no treatment-related deaths.